BidaskClub upgraded shares of Crispr Therapeutics (NASDAQ:CRSP) from a buy rating to a strong-buy rating in a research report sent to investors on Saturday morning, BidAskClub reports.

Several other brokerages have also issued reports on CRSP. TheStreet raised Crispr Therapeutics from a d rating to a c rating in a research report on Monday, October 28th. Oppenheimer raised their target price on Crispr Therapeutics from $65.00 to $80.00 and gave the company an outperform rating in a research report on Monday, November 25th. Wells Fargo & Co reaffirmed a buy rating on shares of Crispr Therapeutics in a research report on Tuesday, November 19th. Roth Capital raised their target price on Crispr Therapeutics from $65.00 to $100.00 in a research report on Tuesday, November 19th. Finally, Chardan Capital reaffirmed a buy rating and set a $72.50 target price on shares of Crispr Therapeutics in a research report on Monday, November 18th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of Buy and an average price target of $69.54.

Shares of Crispr Therapeutics stock opened at $71.65 on Friday. Crispr Therapeutics has a 1 year low of $22.22 and a 1 year high of $74.00. The firm has a market cap of $3.76 billion, a PE ratio of -20.83 and a beta of 3.15. The stock has a fifty day moving average price of $49.98 and a 200-day moving average price of $46.23. The company has a debt-to-equity ratio of 0.06, a current ratio of 8.32 and a quick ratio of 8.32.

Crispr Therapeutics (NASDAQ:CRSP) last announced its earnings results on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. The firm had revenue of $211.93 million during the quarter, compared to analyst estimates of $6.32 million. As a group, equities analysts anticipate that Crispr Therapeutics will post 0.65 EPS for the current fiscal year.

In related news, Director Pablo J. Cagnoni sold 7,500 shares of the business’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $55.00, for a total value of $412,500.00. Following the completion of the sale, the director now owns 7,500 shares in the company, valued at approximately $412,500. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, President Rodger Novak sold 33,618 shares of the business’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total value of $2,353,260.00. Following the completion of the sale, the president now owns 33,618 shares of the company’s stock, valued at approximately $2,353,260. The disclosure for this sale can be found here. Insiders have sold a total of 56,118 shares of company stock valued at $3,620,760 in the last ninety days. Insiders own 21.40% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Millennium Management LLC purchased a new stake in Crispr Therapeutics in the third quarter worth $4,366,000. Orbimed Advisors LLC purchased a new stake in Crispr Therapeutics in the third quarter worth $21,167,000. Granahan Investment Management Inc. MA grew its stake in Crispr Therapeutics by 8.3% in the third quarter. Granahan Investment Management Inc. MA now owns 34,582 shares of the company’s stock worth $1,418,000 after purchasing an additional 2,655 shares during the period. Barclays PLC grew its stake in Crispr Therapeutics by 42.7% in the third quarter. Barclays PLC now owns 13,877 shares of the company’s stock worth $568,000 after purchasing an additional 4,151 shares during the period. Finally, Stifel Financial Corp grew its stake in Crispr Therapeutics by 18.0% in the third quarter. Stifel Financial Corp now owns 9,795 shares of the company’s stock worth $400,000 after purchasing an additional 1,491 shares during the period. 49.81% of the stock is currently owned by hedge funds and other institutional investors.

Crispr Therapeutics Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Recommended Story: What are no-load funds?

Analyst Recommendations for Crispr Therapeutics (NASDAQ:CRSP)



Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Source link